Cardiovascular Research

Is preconditioning by nicotine responsible for the better prognosis in smokers with acute myocardial infarction?

Authors: Y Birnbaum|||S L Hale|||R A Kloner

Affiliations: + Expand

Abstract

Cigarette smoking is a well-known risk factor for acute myocardial infarction and sudden death. However, a history of smoking consistently has been associated with better hospital outcome in patients with acute myocardial infarction. The mechanism for the better outcome in smokers is not clear. It has been suggested that nicotine may have a "preconditioning-like" effect. This study assesses whether nicotine attenuates myocardial infarct size. Anesthetized rabbits were randomized to receive infusion of nicotine 80 micrograms/kg (n = 13), or saline (n = 12) over 10 min. Twenty minutes after termination of infusion all rabbits underwent 30 min of coronary artery occlusion and 4 h of reperfusion. Risk zone was assessed by blue dye and infarct size by tetrazolium staining. Nicotine did not affect regional myocardial blood flow 15 min after treatment, during occlusion or during reperfusion. Heart rate and mean systemic blood pressure were similar between the groups. Nicotine serum levels during occlusion were 9.5-22.0 ng/ml in the treated group, which are comparable to levels found in human smokers. No differences were found in the risk zone of nicotine compared to control rabbits (26 +/- 2% vs. 23 +/- 2% of the left ventricle, respectively), or infarct size (31 +/- 5% vs. 37 +/- 4% of risk zone). Since no effect on infarct size was found, a third group receiving higher dose of nicotine, 320 micrograms/kg (n = 6), was added. Infarct size was not different from the control group (39 +/- 6% of risk zone). Nicotine, given intravenously before ischemic insult, does not protect the myocardium. A "preconditioning-like" effect of nicotine is probably not the mechanism of reduced mortality in smoking patients with myocardial infarction.

---

Chemical List

Nicotinic Agonists|||Nicotine

---

Reference List

Circulation. 1994 Mar;89(3):1272-81|||Basic Res Cardiol. 1994 Nov-Dec;89(6):524-34|||Am Heart J. 1980 Mar;99(3):342-8|||N Engl J Med. 1991 Jun 6;324(23):1619-25|||Circulation. 1957 Feb;15(2):251-7|||N Engl J Med. 1985 Dec 12;313(24):1511-4|||J Mol Cell Cardiol. 1995 Aug;27(8):1491-506|||Br Med J. 1980 Apr 5;280(6219):967-71|||Br Med J. 1973 Mar 31;1(5856):761-5|||Circulation. 1981 Mar;63(3):546-51|||Naunyn Schmiedebergs Arch Pharmacol. 1991 Nov;344(5):527-31|||N Engl J Med. 1988 Nov 17;319(20):1318-30|||Br Heart J. 1988 Dec;60(6):465-9|||N Engl J Med. 1976 Sep 9;295(11):573-7|||J Cardiovasc Pharmacol. 1988 Jul;12(1):58-64|||Circulation. 1995 Jan 15;91(2):298-303|||Eur J Epidemiol. 1994 Aug;10(4):361-6|||Lancet. 1990 May 19;335(8699):1175-8|||Atherosclerosis. 1978 May;30(1):17-25|||J Am Coll Cardiol. 1984 Nov;4(5):964-71|||Circulation. 1994 Mar;89(3):1282-90|||Ann N Y Acad Sci. 1960 Sep 27;90:161-73|||Am Heart J. 1988 Jan;115(1 Pt 2):267-71|||Am J Cardiol. 1995 Feb 1;75(4):278-9|||Am Heart J. 1970 Jan;79(1):96-102|||Ann N Y Acad Sci. 1960 Sep 27;90:290-301|||Am J Cardiol. 1984 Jan 15;53(2):354-5|||Am J Cardiol. 1984 Jul 1;54(1):56-60|||Circulation. 1993 Jan;87(1):53-8|||Br Med J. 1976 Dec 25;2(6051):1525-36|||Am J Cardiol. 1985 May 1;55(11):1407-11|||Chest. 1978 Sep;74(3):243-6|||Cancer Res. 1981 Feb;41(2):588-92|||Am Heart J. 1985 Sep;110(3):535-41|||Exp Clin Endocrinol. 1994;102(2):111-7|||Circulation. 1992 Apr;85(4):1254-64|||Am J Cardiol. 1995 Feb 1;75(4):232-6|||Eur Heart J. 1991 Jul;12(7):753-9|||Am J Cardiol. 1993 Aug 15;72(5):373-8|||Adv Exp Med Biol. 1990;273:327-37